SAREPTA THERAPEUTICS, INC. Cash and Cash Equivalents, Period Increase (Decrease)
SAREPTA THERAPEUTICS, INC. (SRPT) reported Cash and Cash Equivalents, Period Increase (Decrease) of $495.21 million for the 9-month period ending 2017-09-30, per its 10-Q filed 2017-11-01.
Discontinued › Cash Flow
us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease · last filed 2017-11-01
- SAREPTA THERAPEUTICS, INC. cash and cash equivalents, period increase (decrease) for the quarter ending 2017-09-30 was $449.28M, a 58.58% increase year-over-year.
- SAREPTA THERAPEUTICS, INC. cash and cash equivalents, period increase (decrease) for the quarter ending 2017-06-30 was -$106.38M, a 244.10% decline year-over-year.
- SAREPTA THERAPEUTICS, INC. cash and cash equivalents, period increase (decrease) for the quarter ending 2017-03-31 was $152.30M.
- SAREPTA THERAPEUTICS, INC. cash and cash equivalents, period increase (decrease) for the quarter ending 2016-12-31 was -$272.72M, a 1213.82% decline year-over-year.
- SAREPTA THERAPEUTICS, INC. cash and cash equivalents, period increase (decrease) for fiscal 2016 was $42.12M, a 523.66% increase from fiscal 2015.
- SAREPTA THERAPEUTICS, INC. cash and cash equivalents, period increase (decrease) for fiscal 2015 was $6.75M.
- SAREPTA THERAPEUTICS, INC. cash and cash equivalents, period increase (decrease) for fiscal 2014 was -$183.41M, a 364.65% decline from fiscal 2013.
- SAREPTA THERAPEUTICS, INC. cash and cash equivalents, period increase (decrease) for fiscal 2013 was $69.30M, a 53.10% decline from fiscal 2012.
| Period end | Cash and Cash Equivalents, Period Increase (Decrease) 3 month | Cash and Cash Equivalents, Period Increase (Decrease) 6 month | Cash and Cash Equivalents, Period Increase (Decrease) 9 month | Cash and Cash Equivalents, Period Increase (Decrease) 12 month | Cash and Cash Equivalents, Period Increase (Decrease) 371 month | Cash and Cash Equivalents, Period Increase (Decrease) 374 month | Cash and Cash Equivalents, Period Increase (Decrease) 377 month | Cash and Cash Equivalents, Period Increase (Decrease) 380 month | Cash and Cash Equivalents, Period Increase (Decrease) 383 month | Cash and Cash Equivalents, Period Increase (Decrease) 386 month | Cash and Cash Equivalents, Period Increase (Decrease) 389 month | Cash and Cash Equivalents, Period Increase (Decrease) 392 month | Cash and Cash Equivalents, Period Increase (Decrease) 395 month | Cash and Cash Equivalents, Period Increase (Decrease) 398 month | Cash and Cash Equivalents, Period Increase (Decrease) 401 month | Cash and Cash Equivalents, Period Increase (Decrease) 404 month |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2017-09-30 | $449.28M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-01 | $342.91M derived: sum of 2 quarters · filed 2017-11-01 | $495.21M 10-Q · filed 2017-11-01 | $222.49M derived: sum of 4 quarters · filed 2017-11-01 | ||||||||||||
| 2017-06-30 | -$106.38M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-03 | $45.93M 10-Q · filed 2017-08-03 | -$226.79M derived: sum of 3 quarters · filed 2017-08-03 | $56.53M derived: sum of 4 quarters · filed 2017-11-01 | ||||||||||||
| 2017-03-31 | $152.30M 10-Q · filed 2017-05-04 | -$120.42M derived: sum of 2 quarters · filed 2017-05-04 | $162.90M derived: sum of 3 quarters · filed 2017-11-01 | $236.72M derived: sum of 4 quarters · filed 2017-11-01 | ||||||||||||
| 2016-12-31 | -$272.72M derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-28 | $10.60M derived: sum of 2 quarters · filed 2017-11-01 | $84.42M derived: sum of 3 quarters · filed 2017-11-01 | $42.12M 10-K · filed 2017-02-28 | ||||||||||||
| 2016-09-30 | $283.32M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-01 | $357.14M derived: sum of 2 quarters · filed 2017-11-01 | $314.84M 10-Q · filed 2017-11-01 | $339.32M derived: sum of 4 quarters · filed 2017-11-01 | ||||||||||||
| 2016-06-30 | $73.82M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-03 | $31.52M 10-Q · filed 2017-08-03 | $56.00M derived: sum of 3 quarters · filed 2017-08-03 | $42.28M derived: sum of 4 quarters · filed 2017-08-03 | ||||||||||||
| 2016-03-31 | -$42.30M 10-Q · filed 2017-05-04 | -$17.82M derived: sum of 2 quarters · filed 2017-05-04 | -$31.54M derived: sum of 3 quarters · filed 2017-05-04 | -$36.44M derived: sum of 4 quarters · filed 2017-05-04 | ||||||||||||
| 2015-12-31 | $24.48M derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-28 | $10.77M derived: sum of 2 quarters · filed 2017-02-28 | $5.87M derived: sum of 3 quarters · filed 2017-02-28 | $6.75M 10-K · filed 2017-02-28 | ||||||||||||
| 2015-09-30 | -$13.72M derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-07 | -$18.62M derived: sum of 2 quarters · filed 2016-11-07 | -$17.73M 10-Q · filed 2016-11-07 | $3.52M derived: sum of 4 quarters · filed 2017-02-28 | ||||||||||||
| 2015-06-30 | -$4.90M derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-09 | -$4.01M 10-Q · filed 2016-08-09 | $17.24M derived: sum of 3 quarters · filed 2017-02-28 | -$33.22M derived: sum of 4 quarters · filed 2017-02-28 | ||||||||||||
| 2015-03-31 | $885.00K 10-Q · filed 2016-05-05 | $22.14M derived: sum of 2 quarters · filed 2017-02-28 | -$28.32M derived: sum of 3 quarters · filed 2017-02-28 | $25.34M derived: sum of 4 quarters · filed 2017-02-28 | ||||||||||||
| 2014-12-31 | $21.25M derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-28 | -$29.20M derived: sum of 2 quarters · filed 2017-02-28 | $24.45M derived: sum of 3 quarters · filed 2017-02-28 | -$183.41M 10-K · filed 2017-02-28 | ||||||||||||
| 2014-09-30 | -$50.45M derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-05 | $3.20M derived: sum of 2 quarters · filed 2015-11-05 | -$204.67M 10-Q · filed 2015-11-05 | -$221.34M derived: sum of 4 quarters · filed 2016-02-25 | ||||||||||||
| 2014-06-30 | $53.65M derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-06 | -$154.21M 10-Q · filed 2015-08-06 | -$170.89M derived: sum of 3 quarters · filed 2016-02-25 | -$53.43M derived: sum of 4 quarters · filed 2016-02-25 | ||||||||||||
| 2014-03-31 | -$207.86M 10-Q · filed 2015-05-07 | -$224.54M derived: sum of 2 quarters · filed 2016-02-25 | -$107.08M derived: sum of 3 quarters · filed 2016-02-25 | -$118.82M derived: sum of 4 quarters · filed 2016-02-25 | $49.10M 10-Q · filed 2014-05-08 | |||||||||||
| 2013-12-31 | -$16.68M derived: 10-K 12 month − 10-Q 9 month · filed 2016-02-25 | $100.78M derived: sum of 2 quarters · filed 2016-02-25 | $89.05M derived: sum of 3 quarters · filed 2016-02-25 | $69.30M 10-K · filed 2016-02-25 | $256.96M 10-K · filed 2014-03-03 | |||||||||||
| 2013-09-30 | $117.46M derived: 10-Q 9 month − 10-Q 6 month · filed 2014-11-06 | $105.72M derived: sum of 2 quarters · filed 2014-11-06 | $85.98M 10-Q · filed 2014-11-06 | $235.66M derived: sum of 4 quarters · filed 2015-02-26 | $273.64M 10-Q · filed 2013-11-12 | |||||||||||
| 2013-06-30 | -$11.73M derived: 10-Q 6 month − 10-Q 3 month · filed 2014-08-07 | -$31.48M 10-Q · filed 2014-08-07 | $118.20M derived: sum of 3 quarters · filed 2015-02-26 | $131.69M derived: sum of 4 quarters · filed 2015-02-26 | $156.19M 10-Q · filed 2013-08-08 | |||||||||||
| 2013-03-31 | -$19.74M 10-Q · filed 2014-05-08 | $129.93M derived: sum of 2 quarters · filed 2015-02-26 | $143.43M derived: sum of 3 quarters · filed 2015-02-26 | $137.35M derived: sum of 4 quarters · filed 2015-02-26 | $167.92M 10-Q · filed 2013-05-09 | |||||||||||
| 2012-12-31 | $149.67M derived: 10-K 12 month − 10-Q 9 month · filed 2015-02-26 | $163.17M derived: sum of 2 quarters · filed 2015-02-26 | $157.09M derived: sum of 3 quarters · filed 2015-02-26 | $147.76M 10-K · filed 2015-02-26 | $187.66M 10-K · filed 2013-03-15 | |||||||||||
| 2012-09-30 | $13.50M derived: 10-Q 9 month − 10-Q 6 month · filed 2013-11-12 | $7.41M derived: sum of 2 quarters · filed 2013-11-12 | -$1.92M 10-Q · filed 2013-11-12 | -$8.37M derived: sum of 4 quarters · filed 2014-03-03 | $37.99M 10-Q · filed 2012-11-07 | |||||||||||
| 2012-06-30 | -$6.08M derived: 10-Q 6 month − 10-Q 3 month · filed 2013-08-08 | -$15.41M 10-Q · filed 2013-08-08 | -$21.86M derived: sum of 3 quarters · filed 2014-03-03 | -$29.70M derived: sum of 4 quarters · filed 2014-03-03 | $24.49M 10-Q · filed 2012-08-07 | |||||||||||
| 2012-03-31 | -$9.33M 10-Q · filed 2013-05-09 | -$15.78M derived: sum of 2 quarters · filed 2014-03-03 | -$23.61M derived: sum of 3 quarters · filed 2014-03-03 | $7.29M derived: sum of 4 quarters · filed 2014-03-03 | $30.57M 10-Q · filed 2012-05-10 | |||||||||||
| 2011-12-31 | -$6.45M derived: 10-K 12 month − 10-Q 9 month · filed 2014-03-03 | -$14.28M derived: sum of 2 quarters · filed 2014-03-03 | $16.62M derived: sum of 3 quarters · filed 2014-03-03 | $6.32M 10-K · filed 2014-03-03 | $39.90M 10-K · filed 2012-03-13 | |||||||||||
| 2011-09-30 | -$7.83M derived: 10-Q 9 month − 10-Q 6 month · filed 2012-11-07 | $23.07M derived: sum of 2 quarters · filed 2012-11-07 | $12.77M 10-Q · filed 2012-11-07 | $10.39M derived: sum of 4 quarters · filed 2013-03-15 | $46.36M 10-Q · filed 2011-11-08 | |||||||||||
| 2011-06-30 | $30.91M derived: 10-Q 6 month − 10-Q 3 month · filed 2012-08-07 | $20.60M 10-Q · filed 2012-08-07 | $18.22M derived: sum of 3 quarters · filed 2013-03-15 | $17.45M derived: sum of 4 quarters · filed 2013-03-15 | $54.19M 10-Q · filed 2011-08-08 | |||||||||||
| 2011-03-31 | -$10.31M 10-Q · filed 2012-05-10 | -$12.68M derived: sum of 2 quarters · filed 2013-03-15 | -$13.46M derived: sum of 3 quarters · filed 2013-03-15 | |||||||||||||
| 2010-12-31 | -$2.38M derived: 10-K 12 month − 10-Q 9 month · filed 2013-03-15 | -$3.15M derived: sum of 2 quarters · filed 2013-03-15 | -$14.69M 10-K · filed 2013-03-15 | |||||||||||||
| 2010-09-30 | -$775.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2011-11-08 | -$12.31M 10-Q · filed 2011-11-08 | ||||||||||||||
| 2010-06-30 | -$11.53M 10-Q · filed 2011-08-08 | |||||||||||||||
| 2009-12-31 | $37.08M 10-K · filed 2012-03-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |
| Zymeworks Inc. (ZYME) | United States | $1.902B | -12.44 |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| COMPASS Pathways plc (CMPS) | $1.812B | -4.87 | |
| ANI PHARMACEUTICALS INC (ANIP) | United States | $1.810B | 18.77 |